Therapeutic cancer vaccines, an exciting development in cancer immunotherapy, share the goal of creating and amplifying tumor-specific T-cell responses, but significant obstacles still remain to their success. In this meeting pioneering industry and academics will outline the cancer vaccine therapy and immunotherapy with a focus on novel vaccine platforms and antigens, underscoring the renewed optimism that has risen during pandemic.
The field of therapeutic cancer vaccines is fast evolving, and while the diverse platforms or targets are currently being evaluated, valorization of this yet-to-be established innovations stays challenging.
12:00 Walk-in, registration and lunch
13:00 Word of welcome
13:10 Sjoerd van der Burg, Professor of Cancer Immunology & Therapy
13:40 Gerben Moolhuizen, CEO ISA Pharmaceuticals
14:00 Katka Franke, Associate Director Human Immunology Curevac
14:20 Coffee and tea break
14:50 Carl Figdor, Professor of Immunology
15:10 Erik Manting, CEO Mendus AB
15:30 Helen Lavender, Translational Scientist CRUK & Vaccitech Oncology Limited (VOLT)
15:50 Short break
16:05 Interactive session
16:35 Networking drinks
Who can join Biotech Wednesday
Biotech Wednesday is open to all interested organizations and free of charge (max. 3 delegates per organization) HollandBIO members and academia have priority.